" class="no-js "lang="en-US"> Marina Udier - Medtech Alert
Wednesday, December 06, 2023
Marina Udier

Marina Udier

About Marina Udier

Executive with business and leadership experience in multinational, Big Pharma (Novartis), and in private VC backed startup (Nouscom, funded by 5AM, Versant, EQT, Abingworth). Independent Board Director of a NASDAQ listed company.

• Lead a clinical stage IO biotech (50 FTEs) through the first IND submission, regulatory clearance, and initiation of the First in Human clinical trial (multi-site US trial, in Ph2). Oversaw CTA submission of the second clinical candidate in Europe
• Business development and financing: executed €42M private equity financing for an oncology biotech developing cancer vaccine. Executed two licensing and manufacturing agreements with a Big Pharma (Fortune 500) and brought first collaboration product to IND approval.
• Operational leadership: Negotiated partnership, managed alliance, lead development of a Companion Diagnostics required for selection of patients for treatment with Rydapt™ (new AML drug, approved in 2017).
• People leadership: Recruited a predominantly female executive team including CMO, VP Finance, Technical Director, CBO, and HR Head; lead a company with 80%+ female employees. Experience leading virtual, global, multi-cultural teams in US, EU, and Asia.

Related Story

Nouscom Announces Janssen Receives US FDA IND Clearance for VAC85135, an 'Off-The-Shelf' Cancer Immunotherapy Developed using Nouscom's Proprietary Viral Vector Platform

May 17 2022

Nouscom, a clinical stage immuno-oncology company developing both off-the-shelf and personalized cancer neoantigen immunotherapies, today […]